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care in England and the US: the ‘accidental
logics’ of political settlements
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Abstract: This article considers how the ‘accidental logics’ of political settlements
for the English National Health Service (NHS) and the Medicare and Medicaid
programmes in the United States have resulted in different institutional
arrangements and different implicit social contracts for rationing, which we deﬁne
to be the denial of health care that is beneﬁcial but is deemed to be too costly. This
article argues that rationing is designed into the English NHS and designed out of
US Medicare; and compares rationing for the elderly in the United States and in
England for acute care, care at the end of life, and chronic care.
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Introduction
This article compares institutional arrangements for, and consequences of, the
rationing of health care in England and the United States, which we deﬁne to be
the denial of health care that is beneﬁcial but is deemed to be too costly. In this
introduction we outline the argument we develop in the rest of the paper. We ﬁrst
clarify complexities of nomenclature. There is no single UKNational Health Service
(NHS); and, following devolution in 1999, there has been increasing divergence
of policies between the NHSs of England and Scotland, Wales and Northern
Ireland (Connolly et al., 2011). In this article we refer to England where policies for
its NHS differ from the other NHSs, and use the United Kingdom where the four
NHSs have common features and where the United Kingdom has been used for
international comparisons. Within the English NHS, as there have been regular
structural reorganisations since 1991 (Klein, 2010), we use the term ‘purchaser’
to cover their successive organisational forms (district health authorities, primary
care groups, two types of primary care trusts and clinical commissioning groups
from 2013).
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This article begins by considering the differences in the power of the executive
in each country, which we argue shape legislative reforms of health care. In the
United States, legislative process, the checks and balances on the power of the
executive mean current vested interests are crucial actors in any political settlement
that seeks to reform health care. The concessions deemed necessary to those interests
to enact legislation mean that they continue to be key players after legislation has
been enacted. In England, the government can largely ignore the vested interests that
will cease to matter after legislative reform of health care is enacted, and so can focus
on the political settlement with those who will be key players in a future system.
These differences have been powerfully demonstrated by the comparative difﬁculty
in the United States and ease in England of implementing two current controversial
reforms. The Affordable Care Act (ACA) (Obamacare) was central to the policies of
two successful Presidential election campaigns, but, despite the process being crafted
to enable important concessions to be made in framing the legislation, there was a
struggle for this legislation to be enacted, and after being enacted, it was subject to, in
2012, challenges in the Supreme Court, and, in 2013, to Republican threats to shut
down the Federal Government if the Act were not repealed or delayed (Jost, 2014).
The English policies of the Secretary of State for Health (2010) did not feature in the
2010 campaign of the Conservative Party, contradicted the commitment of the
Coalition Government (Cabinet Ofﬁce, 2010) to ‘stop the top-down reorganizations
of the NHS that have got in the way of patient care’ (p. 24), but have been in a
process of implementation since the 2010 election (Timmins, 2012). We outline two
landmark political settlements that have shaped the institutional arrangements for
health care in each country, the creation of theMedicare andMedicaid programmes
in the United States and the NHS in England. Each has had what Tuohy (1999)
describes as ‘accidental logics’, which she describes as follows: ‘episodes of policy
change have required a conﬂuence of factors in the broader political arena; the
resultant systems have been shaped by the climate of ideas and the constellation of
interests that exist at the time that such a conﬂuence occurs. Once established, the
institutional mix and structural balance of these systems intersect to generate a
distinctive logic that governs the behaviour of participants and the ongoing
dynamics of change’ (p. 7). Hence the different ‘accidental logics’ have path-
dependent consequences for the different institutional arrangements for health
care, which we argue imply different social contracts for rationing health care. We
explain how, in England, explicit and implicit rationing is designed into the NHS;
but, in the United States, rationing is deemed to be unacceptable within the
systems of health care and hence mainly applies through user charges and in
variations in, and lack of, insurance. We explain why the principal challenge of
rationing in both nations is over decisions on the capacity of new technology to do
more for the elderly. Hence we focus our comparisons on how different institu-
tional arrangements ration the care of the elderly, in the United States and England
for acute and end of life (EOL) care, where technology matters, and chronic care,
where technology tends to be less important.
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Political settlements and their institutional consequences
As Marmor and McKissick (2012) argue, the US Medicare programme was
designed to offer ﬁnancial protection from the risk of ﬁnancial disaster due to
the escalating costs of health care facing the elderly, and its direct correlation of
rising elderly poverty rates, by transferring the responsibility for payment to the
government (i.e. to social insurance contributors and to taxpayers, including
younger Americans); ‘but to do so without interfering signiﬁcantly with the
traditional organisation of American medicine’ (p. 59, emphasis in original).
Partly to seek peace with organised medicine and partly to avoid impressions that
Medicare was somehow ‘second tier’ coverage, the programme’s designers also
adopted payment arrangements that largely mimicked those to which they were
accustomed in private Blue Cross and Blue Shield insurance plans: payment based
on usual and customary charges. (Hospitals received retrospective payment of
their ‘actual’ costs for Medicare patients.) Its payment methods were quickly
derided as a ‘blank check for inﬂation’ and so they proved to be. Tuohy (1999: 60)
observes that ‘In the design of the Medicare program, American policy makers
made even greater concessions to the interests of providers and private insurers
than was the case in Canada’. As Brown (2011, 2012a), argues, these concessions
may have been necessary to create the coalition required in the United States for
the political settlements that extended coverage.
The outcome of legislative reforms of health care in the United States is that the
institutional arrangements are those of a mixed private-public system with a rheto-
rical bias towards conﬁning government to ﬁlling gaps in private coverage. The
irony is that the government provides insurance for approximately one-third of
Americans, including those over 65, veterans of the armed forces, active military
servicemen and women as well as many Americans with disabilities, Native
Americans and the poor through Medicaid. The private health insurance industry
coversmany employedAmericans and their families, but historically, tens of millions
have been uninsured. In 2011, the United States was one of the three countries where
less than half the total costs of health care were publicly ﬁnanced; the other twowere
Chile and Mexico (OECD, 2013a). US health care has been delivered by various
organisational forms, but is generally characterised by paying hospitals negotiated
prospective sums per clinical episode and physicians fees for services delivered, some
consumer cost sharing and a mix of for-proﬁt and not-for-proﬁt hospitals, with
patients often having direct access to specialists. In the United States, acute and EOL
care are covered by the Medicare programme; but long-term chronic care is not
(apart from treatment for renal failure, short-term skilled nursing services directly
following a hospital stay, and home health care services for beneﬁciaries unable to
care for themselves).
The objectives of the creation of the NHS were to achieve equity of access by
need, which justiﬁed the principal elements of ‘socialised medicine’: universal
coverage, access free at the point of delivery, ﬁnance by taxation, regulation of the
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distribution of general practitioners (GPs), and the nationalisation of voluntary
and local government hospitals. These principal elements of ‘socialised medicine’
still apply to each NHS in the United Kingdom. Following the creation of the
NHS, private medical care became of marginal importance: it is typically a perk of
employment and generally directed at elective care for those of working age. In
2011, the United Kingdom was one of the three countries where over 80% of the
total costs of health care were publicly ﬁnanced; the other two were Denmark and
Sweden (OECD, 2013a). The power of the executive in the British Parliamentary
systemmeant that despite the impacts of the radical legislative changes on insurers
and hospitals in the creation of the NHS in the 1940s, they barely feature in
accounts of the political settlements, which focus on hospital specialists and GPs
(Webster, 1991; Klein, 2010). These settlements delivered effective systems of cost
control: specialists are paid salaries; GPs’ contracts are based on payment by
capitation; and access to specialists is via GPs who act as gatekeepers. This
settlement also resulted in rationing being designed into the NHS though what
Klein (2010) described as an implicit ‘bargain between the State and the medical
profession’, in which ‘Politicians in the Cabinet made the decisions about how
much to spend; doctors made the decisions about which patient should get
what kind of treatment’ (p. 61). And the commitment to equity resulted in the
development of policies that aim to distribute that budget geographically in rela-
tion to the estimated relative need of populations (Bevan, 2009). A paradoxical
outcome has been that, despite some fears of the medical profession at the time of
the creation of the NHS that it would result in them being subject to state control
(see e.g. Webster, 1988), this arrangement has allowed them considerable clinical
autonomy as compared with the mixed public/private system in the United States.
Institutional arrangements and their implicit social contracts
In England, the accidental logic of the political settlement that created the NHS
was a set of institutional arrangements for rationing health care (including the
three types of care we examine later) that create an implicit Universal Social
Contract (USC), for which Daniels (1990, 2003) and Dworkin (1992, 2000)
provide different philosophical justiﬁcations, which may be summarised as
follows. Because we are all behind a ‘veil of ignorance’ about our future health
and incomes, the best form of insurance against an uncertain future (from both
severe illness and poverty) is collective. Indeed Arrow (1963: 947) argued that,
although such a USC looks to be justiﬁed by a preference for redistribution, it ‘can
be reinterpreted as a desire for insurance’. In this USC insurance is required
(and hence constrains choice), independent of ability to pay (and not based on
individual risk) and thus in effect is a system of taxation (Evans, 1987). Aneurin
Bevan (1978: 100), the Minister who created the NHS emphasised the redis-
tributive nature of its USC: ‘Society becomes more wholesome, more serene and
spiritually healthier, if it knows that its citizens have at the back of their
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consciousness the knowledge that not only themselves, but all their fellows have
access when ill, to the best that medical skill can provide’. Daniels and Dworkin
argue that such a USC provides a justiﬁcation for the principle of ‘lifetime
rationing’ that, ceterus paribus, the young ought to have priority over the old;
although other differences between the young and the old may mean that priority
may be given to treat the young on grounds other than age, such as the higher risks
from treatment for the old and better outcomes for the young. Dworkin (2003:
314) illustrates the principle of lifetime rationing through his thought experiment
in an idealised state, in which there is equity of wealth and income, no information
asymmetry on health care for patients, insurers are denied information on enrolees
health, and health care decisions are left to ‘as free a market as we can imagine’
(p 312). Individuals have to decide, in this idealised state, what they are prepared
to pay, over their lifetimes, for insurance cover for health care. Dworkin argues
that: ‘Most young people on reﬂection would not think it prudent to buy insur-
ance that could keep them alive by expensive medical intervention, for four or ﬁve
months at the most if they had already lived into old age. They would think it
wiser to spend what that insurance would cost on better health care earlier, or on
education, or training or investment that would, provide greater beneﬁt or more
important security’ (p 314). Daniels emphasises that the principle of lifetime
rationing avoids the utilitarian problem of interpersonal comparisons because it
operates ‘within a life and not between lives’ (Daniels (1990: 96, emphasis in
original) and thus justiﬁes a fundamental element of cost-effectiveness analysis,
which gives priority to services directed at the young simply because of their
greater potential life years. Daniels also argues that the principle of lifetime
rationing implies entitlement to a ‘fair innings’ so that resources are allocated to
achieve greater equity in life expectancy, which Williams (1997) argued ought to
take account of quality of life.
The accidental logic of the political settlement that created Medicare and
Medicaid has striking consequential differences from those of the NHS.Medicare,
as Marmor argued, breaches ‘one version of social solidarity’ by separating the
beneﬁciaries, who are entitled to coverage because they are ‘retired’ (on grounds of
age, disability or renal failure), from those who are in employment, and are left
‘ﬂailing in the sea of either uncertain coverage or added constraints on their
choices within insurance coverage’ for themselves and their families (Marmor,
2012: 47). This follows from Medicare being based on an implicit Intergenera-
tional Categorical Social Contract (ICSC), on the principle that its beneﬁciaries
have earned their privileged entitlement to health care when ‘retired’ through the
ﬁnancial contributions they made when they were in work: asMarmor points out,
there is ‘no evidence that any substantial number of Americans’ would want
to end Medicare’s relatively generous coverage’ (Marmor, 2012: 47). No such
entitlement applies to Medicaid ﬁnanced by transfer payments from taxpayers
as welfare for the eligible poor. These various insurance arrangements give
philosophical justiﬁcation neither for the principles of lifetime rationing, nor using
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the criteria of cost-effectiveness, nor a fair innings; and have resulted, as Daniels
(1990) observed, as lifetime rationing in reverse: policymakers have been ‘more
willing to impose stricter eligibility requirements and budget ceilings in Medicaid,
most of whose recipients are young women and children, than alter our practices
for the dying elderly’. Indeed about one-third of Medicaid spending goes to long-
term care, and the programme ‘spends more than ﬁve times as much on each
senior in long-term care as it does on each poor child’ (Bernstein 2012: A1).
In practiceMedicare is ﬁnanced by complex arrangements from a Pay As YouGo
(PAYG) scheme and its trust fund. As the costs ofMedicare increase with an ageing
population, there is confusion over the implications of the ‘insolvency’ of its trust
fund. The implications for the problem of insolvency of pensions ﬁnanced by a
PAYG scheme with an aging population are, in principle, quite straightforward:
which are to extend the age of retirement (Barr andDiamond, 2006). As we explain
below, however, the main driver of increases in costs of health care with an aging
population are not caused simply by increases in life expectancy only, but because
developments in technology mean that more can be done for those who live longer.
Medicare’s ICSC is based on the promise that the generation who are retired are
entitled to whatever new technology has been proven to be effective, regardless of
cost. This promise is designed to escalate the costs of Medicare as developments
in technology mean that expenditures on current beneﬁciaries will exceed their
contributions when in work (which ﬁnanced care for the previous generation of
retirees with ‘old’ technology), and hence requires increasing ﬁnancial contributions
from each generation in work.
Institutional arrangements for determining expenditures on health care
and the distribution of resources
We compare the outcomes of the different institutional arrangements for determin-
ing expenditures on health care in the United States and the United Kingdom/
England and the distribution of resources to the NHS in England and the Medicare
programme in the United States.
Figure 1 shows total costs of health care as a percentage of GDP in the United
States and the United Kingdom over 50 years (1960–2010). In the United King-
dom, the outcome of the top-down process of cost control of the NHS has been
that constrained growth in total costs of health care has been the norm. Indeed, the
two ‘ﬁnancial crises’ of England’s NHS in the past 30 years, in the winters of
1988–1989 and 1999–2000, were ones of ‘underfunding’ after two decades of
limited growth (in the 1980s and 1990s) (Bevan and Robinson, 2006). In each
case these crises were followed by increases in NHS funding and the decade of the
2000s was one of sustained real growth.
The disparate components of US health care largely generate costs from the
bottom up with the outcome that the dominant pattern of the total costs of
US health care is one of continued escalation. Various empirical studies have
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investigated and rejected common perceived causes of why the United States is an
outlier in international comparisons because of its exceptional high and increasing
costs of health care. These include wasteful administrative costs, more defensive
medicine, expensive care for the terminally ill, the spread of health insurance, and
its ageing population (Newhouse, 1993; Reinhardt et al., 2004; Anderson et al.,
2005; Smith et al., 2009). One reason for the United States being an outlier is the
high prices paid for health care (Anderson et al., 2003). And, although studies
have consistently shown that applying current costs by age group has limited
effects on future costs (Barer et al., 1987; Zweifel et al. 1999), Smith et al. showed
that a second explanation is the combination of aging and technology, which
accounted for over 60% of the increase in costs in the United States from 1960 to
2007: i.e. developments in technology meant increasingly more has been done
for ageing populations. The next three sections of this article that follow are
our examination of how different institutional arrangements impact on the care of
the elderly, in the United States and England for acute and EOL care, where
technology matters, and chronic care, where technology is much less important.
Before we do so, we make two comparisons in the way total spend on health care
is determined and how it has been distributed.
In England the NHS budget is determined in relation to other pressures on the
exchequer and since 1977, that budget has been distributed with the objective of
securing ‘equal opportunity of access for those at equal risk’ (Bevan, 2009).
Although that policy reduced the range of variations of actual spend per capita
(adjusted for risk) from nearly twofold in the 1980s (Beech et al., 1990), to about
1.3-fold in the 2000s (Department of Health, 2007); this had been accom-
panied by widening inequalities in health outcomes. So, from 1999, Ministers
added a second objective: to reduce ‘avoidable’ health inequalities, which is
consistent with rationing on the equitable basis of a ‘fair innings’ (Bevan, 2009).
These processes of resource allocation are intended to ensure that in different
areas doctors’ rationing decisions are made within an equitable distribution of
0.0
5.0
10.0
15.0
20.0
1960 1970 1980 1990 2000 2010 2020
United Kingdom United States
Figure 1. Total expenditure on health care as % GDP for the United States and the United
Kingdom, 1960–2011. Source: OECD (2013b).
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NHS resources. Medicare itself enfranchised millions of previously uninsured
older Americans, many of whom were poorer and minorities, emphasises an
equality of beneﬁts (and equal cost sharing) across its enrollees and has recently
begun to focus on reducing inequalities in both health outcomes and access
(Eichner and Vladeck, 2005). But, despite this commitment to equity within
Medicare, wide variations in spend per capita have been consistently documented
by the Dartmouth Atlas, after accounting for differences in cost allowances
(Skinner, 2011), age, sex and race. Gottlieb et al. (2010) reported that, in 2006,
adjusted total Medicare spend per capita varied threefold (ranging from about
$15,000 in Miami to $5000 in Honolulu). The unintended opportunity costs of
US arrangements include incomplete coverage and comparatively poor health
outcomes: OECD (2013c) points out that in the United States, ‘Life expectancy is
now more than a year below the OECD average of 80.1, compared to one year
above the average in 1970’ (p. 1).
Acute care
Aaron and Schwartz (1984) compared acute care in the United States and ‘Britain’
(which they use to describe both England and the United Kingdom) in the 1980s,
which was during a decade of limited growth for the NHS (see Figure 1). They
found rationing in Britain not by reducing quality to increase numbers treated, but
by doctors within the NHS using the principles of lifetime rationing and cost-
effectiveness, from constraints on supply and by waiting lists. The evidence for
lifetime rationing was that the United Kingdom had lower rates than the United
States for haemodialysis, which largely affects the elderly (we discuss this further
below), but not for haemophilia, which is usually discovered in childhood (p. 37).
The evidence for rationing by cost-effectiveness (Williams, 1985) was that British
rates of hip replacements and coronary artery surgery were 80% and 10% of US
rates (p. 92). The evidence of rationing by constraints was for scanners in Britain,
which they saw as causing ‘a substantial reduction in the quality of care’ (p. 72);
but they suggested that use of diagnostic X-rays in the United States was excessive.
The persistent problem of rationing by waiting (p. 14) has notoriously plagued the
NHS since it began; its perceived absence in the United States is often used as an
argument against ‘socialised medicine’.
Although the later comparative study by Aaron et al. (2005) in the 2000s
(during the decade of sustained growth in NHS funding – see Figure 1), reported
dramatic increases in rates of treatment in Britain for renal failure, hip replace-
ments and coronary artery surgery, the British rates for renal failure and coronary
artery surgery were still below those for the United States. The former reﬂected
differences in what physicians believed to be appropriate care (pp. 43–44), and
the latter large differences in supply: e.g., New Jersey, with about one-seventh
of the UK’s population, had over 50% more cardiologists (p. 73). They inter-
preted the low British rates for coronary artery surgery as evidence of rationing, in
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that patients who could beneﬁt were denied treatment, but speculated that the US
rates may have been too high (p. 76). They also found that the United Kingdom
continued to have much lower rates of diagnostic services than the United States
(in use of CT scanners and MRI equipment), which they saw as both eroding
quality of care as compared with the United States and as a sound rationing
response (p. 92). Figure 2 gives rates for the United Kingdom as a percentage of
those for the United States for selective diagnostic and treatment activities for
2006 using the most recent comparative data (OECD, 2011), which do not report
rates by age. These show the United Kingdom to have had much lower rates than
the United States for treatment for renal failure, expensive diagnostic services,
coronary artery surgery, and knee replacements; but rates of hip replacements
were higher in the United Kingdom than in the United States.
During the 2000s, there were two key developments that changed the ways in
which the NHS in England rations care. First, the Labour Government’s over-
riding objective of the increases in funding the NHS in England in the 2000s was
to end crude rationing by waiting. The government’s targets for the time patients
had to wait from seeing a GP to being admitted to hospital for an elective opera-
tion were reduced from over 2 years (in 2000) to 18 weeks (in 2005) (Thorlby and
Maybin, 2010). This was achieved by regimes of strong performance management
(based on strategies of ‘naming and shaming’ and ‘targets and terror’); these
approaches were not introduced in the NHSs in Scotland, Wales and Northern
Ireland where, although each too had similar increases in funding, there was
less progress in reducing long-waiting times (Bevan and Hood, 2006; Connolly
et al., 2011).
Second, since 1999, explicit rationing of new technology has been the respon-
sibility of the National Institute for Health and Clinical Excellence (NICE) (2012).
Figure 2. UK rates of treatment and use of diagnostic services as a percentage of US rates
(2006). Sources: OECD (2011).
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NICE does not approve for NHS coverage all drugs and devices that the UK’s
medicines and healthcare products regulatory agency licenses, but recommends
what should be available on the NHS in a deliberative process with reference to
evidence from cost-effectiveness analysis. This was how the Labour Government
intended to end geographical variations in access to care (‘postcode rationing’)
(Klein, 2010).
NICE normally considered interventions costing less than £20k ( ~$34.4k at
2008 prices) per quality-adjusted life year (QALY) to be cost-effective; the least
cost-effective intervention NICE approved cost £49k ($84k)/QALY (Steinbrook,
2008). Claxton et al. (2013) suggest that the threshold should be below £20k (at
2008 prices) otherwise the NHS by funding new technology could drive out current
care that is more cost-effective. NICE provides a remarkable contrast with ana-
logous institutions in the United States. As Marmor observed over 10 years ago,
the ‘profound’ question whether Medicare ‘should ﬁnance all the medical care
passing the test of efﬁcacy’ (Marmor, 2000: 154) has remained unresolved. After
decades of debate the United States has still not agreed to add cost to effectiveness in
its formal decisions on the treatments Medicare covers. Neumann and Weinstein
(2010) criticise the limits on the new Patient-CenteredOutcomes Research Institute,
created by the ACA, in conducting comparative-effectiveness research and speciﬁ-
cally the prohibition from ‘developing or using cost-per-QALY thresholds’ on the
grounds that this uses the principle of lifetime rationing, which ‘seems to reﬂect
long-standing concerns. The worry is that the metric unfairly favours younger
and healthier populations’ (p. 1496). They point out that this rejection of cost-
effectiveness analysis leads into the funding of care, which Dworkin argued against,
with unintended consequences:
Taken literally, it means that spending resources to extend by a month the life of a 100-
year-old person who is in a vegetative state cannot be valued differently from spending
resources to extend the life of a child by many healthy years. Though the ACA may be
seeking to avert discrimination, it instead helps to perpetuate the current system of
implicit rationing and hidden biases (p. 1496).
A recent joint report by Age UK and the Royal College of Surgeons (2012)
pointed out that, until October 2012, NHS bodies were exempt from provisions of
the Equality Act 2010 that outlawed discrimination on grounds of age; but now
such discrimination is illegal and so decisions ought to be made on clinical
grounds without reference to age. Furthermore this is now part of the NHS
Constitution (Department of Health, 2012). The Report found evidence that rates
of surgery consistently declined with age with indications of rationing by age for
those over 85 in England, which had also been identiﬁed by Judge et al. (2010).
This suggests that ending age discrimination would create considerable extra
demand for services in England. The medical director of the NHS, Sir Bruce
Keogh, in evidence to the Public Accounts Committee of the House of Commons
reported being ‘deluged’ with letters of complaint over inconsistency in the
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thresholds for surgery for which purchasers would pay for hip replacements and
cataract operations in the winter of the ﬁrst year of austerity for the English
NHS (2010/11); and that the Royal College of Surgeons is working on value
based commissioning of elective surgical care, to deﬁne appropriate access
thresholds (UKHouse of Commons, Committee of Public Accounts, 2013, ev 25).
The implications of the NHS constitution proscribing aged-based discrimination
are to end the principles of ‘lifetime rationing’, a ‘fair innings’ and the use of
QALYs as a measure of effectiveness to give priority to the young over the old;
NICE still uses QALYs but recognises that this use of cost-effectiveness analysis is
controversial (http://publications.nice.org.uk/guide-to-the-methods-of-technology-
appraisal-2013-pmg9). We return to this point in our discussion.
Care at the EOL
Superﬁcially, for EOL care, the ﬁrst comparative impressions are of considerable
common ground in the objectives of the two systems in England and the United
States. For both systems the central problem of EOL care is deﬁned as not
when, but rather where and how one dies, with a corollary that better EOL care
occurs not in hospitals but in homes or hospices, sites that are often both more
comfortable for patients and families and less costly. Both systems increasingly
endorse the development of alternative EOL settings (e.g. hospices), treatments
(e.g. palliative care), and trajectories (e.g. evidence-based ‘pathways’). Both envi-
sage the expansion of personnel trained to give a range of largely non-clinical
services, including counselling and pain management. Both seek to make patients,
families, and the public at large better acquainted with these less clinically
aggressive options and their advantages. However, the very different institutional
arrangements have resulted in different emphases in considering how to resource
and organise EOL care.
The Department of Health grounds the case for new directions in EOL care
primarily on the contention that less aggressive, intensive, and intrusive hospital
care is better for, and preferred by, a great many patients. For example, between
56% and 74% of people surveyed prefer to get care and die in their own home, or
a care (nursing) home instead of an acute hospital; but, in 2006, 58% of deaths
took place in an acute hospital and only 35% in a home or care home. The
overriding argument for reform is to meet individuals’ preferences, but doing so
would also lead to impressive savings: e.g., about £4.5 million would be available
annually for investment in community services if the 40% of patients who died in
an acute hospital in Shefﬁeld in October 2007 without ‘medical needs which
required them to be admitted’ had died in a less intensive setting (House of
Commons, Public Accounts Committee, 2009: 7, 9 and 10).
Since the late 1980s, for acute services in England, the emphasis has been on
provider competition to replace a planned economy of health care (except from
1997 to 2002) (Bevan and Robinson, 2006; Klein, 2010). For EOL reform,
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however, the emphasis has been on planning: that is publicly driven strategies that
elaborate and incorporate patients and providers (both NHS clinicians and local
social service agencies) into care plans, that aim to keep EOL patients at home,
with hospital stays the exception. This line of policy gained prominence in 2008
when the NHS adopted its End of Life Care Strategy, festooned with ambitious
objectives ensuring that ‘pain and suffering are kept to an absolute minimum’, that
‘caregivers are appropriately supported’, and that ‘services provide good value for
the money to the taxpayer’ (Gray, 2011). In 2011, the NHS went further, issuing
new evidence-based EOL guidance. With regards to EOL care, the arrival in ofﬁce
of the Conservative/Liberal Coalition in 2010 so far seems to have had little effect.
Despite the NICE guidance, EOL care in England triggers controversy as shown
by different purchasers being said to have followed different philosophies and
protocols, raising again the spectre of ‘postcode rationing’. We mentioned above
that aged-based discrimination is ofﬁcially proscribed, but the aged may be short-
changed nevertheless, because, as observed in 2000, ‘some services operate with
upper age limits, which may not be openly publicised but which are real barriers
nevertheless’ (King’s Fund, 2000: 4). Klein and Maybin wonder whether NICE’s
willingness to attach special value to drugs for terminal cancer care in the last few
months of life raises questions of consistency: ‘Should not the same extra value be
attached to the last few months of life for older people in hospital?’ For that
matter, are prevailing priority setting processes systemically biased to favour
‘interventions as distinct from focusing on the quality of care?’ (Klein andMaybin,
2012: ix, 43). The coordination of health care with social services, though
essential to sound EOL planning, is itself tortuously difﬁcult to plan, because the
two sectors are organisationally and ﬁnancially distinct. Nor does more humane
and cost effective EOL care come free. In March 2012, e.g., Andrew Lansley, the
then Secretary of State for Health, announced that the NHS would invest
1.8 million pounds (supplemented by 2.5million pounds from the Marie Curie
Cancer Care Organization) to support eight pilot sites at which to develop ‘a new
patient funding system for all providers of palliative care’ (http://www.they
workforyou.com/debates/?id=2012-03-27a.1317.6). It also remains uncertain
whether plans launched amid major new infusions of cash into the NHS in the
early and middle 2000s will survive the straitened circumstances of the English
budget today and for the foreseeable future.
In the United States there appears to be a different emphasis on the continued
scope for medical progress and its capacity to improve and prolong the lives of the
aged, and a history of strong antagonism to any notion of lifetime rationing. There
is continuing vigilance against cost-minded federal bureaucrats, portrayed by
some politicians as perversely bent on concocting ‘death panels’ designed
expressly to pull plugs on seniors who live too long and cost too much (Rutenberg
and Calmes, 2009). In the United States, needless to say, there exists no analogue
to England’s publicly directed strategic planning for changes in EOL policies or
practices. Gray (2011: 2) notes that none of the recommendations in the Institute
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of Medicine’s report of 1997, Approaching Death, was ‘directed at any speciﬁc
entities – governmental or nongovernmental – that could be held accountable for
implementing them’.
Reform in the US centres on expanding the range of (consumer) choice, on the
consolidation of formal rights for patients and their families to exercise choices
about EOL care, and on the cobbling together of funding sources to pay for
palliative care and kindred services. These reforms – living wills, power of attor-
ney provisions, assisted suicide (illegal in England but authorised in three US states
and under debate in several more), growth of hospices, greater availability of
palliative care, and so on – advance via legal authorities and program budgets at
both the state and federal levels of government and draw encouragement from
foundations (Robert Wood Johnson, for instance) (Brown, 2012b). Under their
Mental Capacity Act of 2005 the English too honour advance statements and
decisions as well as Lasting Powers of Attorney, but what distinctively legitimates
these reforms in the United States is that they simply expand the rights of patients
to fashion their own EOL fates, free of pressures or mandates by government and
its bureaucratic legions. A US government-generated equivalent of the monthly
Newsletter, issued by the National End of Life Care Programme of the National
Health Service, which addressed in its issue of August 2012 such topics as ‘End of
Life Diabetes Care’, would currently be unimaginable.
EOL reformers in the United States worry that even when conversations
between patients and providers are framed by living wills and other legal fortiﬁ-
cations for choice, the ingrained bias towards ‘more’ makes it hard to stop
the clinical juggernaut, which often by deﬁnition is in a hospital setting, not a
home-care based setting, where most Americans, like most English, say they prefer
to die. (As Gawande (2010) notes, it is rarely the case that, clinically speaking,
‘nothing’ can be done at the EOL.) The empowering documents may not be ﬁlled
out or ﬁled properly, or may be ambiguous in the face of the patient’s complex and
rapidly changing clinical conditions. The family may disagree among themselves
about what the incapacitated patient would want done or forgone. Providers may
fear legal repercussions if they cannot prove they did all they could to prolong the
patient’s life. It may be unclear which specialist is in charge, with the authority to
end aggressive treatment. In the United States and the United Kingdom both, EOL
patients determined to see their rightful choices implemented may face a sharp
uphill struggle.
These comparative EOL conundrums admit no evident endpoint. In terms of
objectives, the two nations are gradually converging with aims to offer more
options and choices for patients, more treatment alternatives and more efforts to
accommodate patients and their families’ wishes of dying outside a high-tech
hospital setting. However, institutional arrangements suggest that the EOL care
that is provided puts England and the United States at opposite ends of the cross-
national EOL continuum – a bias towards less is more in England and towards
more is better in the United States.
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Chronic care
One consequence of the original political bargains to pass Medicare in the United
States was it was not designed to cover care for the chronically sick elderly
(Marmor, 2012), although Medicare does now cover some elements of chronic
care. Certainly, the chronic care challenge is signiﬁcant and growing in both
countries. In the United States, an estimated 65% of the Medicare population have
at least two chronic conditions (Wolff et al., 2002) with more than 26% of the
Medicare population suffering from diabetes alone (Fradkin, 2012). For the over
65s in England, over 60% report living with a chronic illness or disability (Ofﬁce of
National Statistics, 2011. In the United States, costs associatedwith chronic illnesses
account for more than 75% of Medicare spend (Sochalski et al., 2009). The ACA
depends on savings in Medicare, which accounted for 20% of total US health care
spend in 2010 (Kaiser Family Foundation, 2011), to meet its health care budget
targets. Similarly, in England, the government has touted restructuring chronic care
as having the potential to improve care quality, constrain future overall costs by
helping people stay healthier for longer and save on the government’s on-going
costs through introducing greater cost sharing on individuals for care homes (‘care
homes’ or ‘nursing homes’ are not under the purview of the NHS).
Whether or not reforms when translated into practice in either the United States
or the United Kingdom will alter the ways in which chronic care is delivered and
paid for remains to be seen. The NHS andMedicare currently both ration chronic
care for the elderly, albeit generally in different ways. Below we offer three
examples of such rationing, which illustrate all three possible outcomes: the ﬁrst is
where there is clear evidence of more severe rationing in England, the second
where there is less rationing in England, and the third is where the principle of
explicit rationing seems to be conspicuously similar but there are differences in
practice, which reﬂect institutional arrangements.
The ﬁrst example is that notorious difference historically between the NHS and
the United States in the availability of costly treatment for renal failure. In the
United States, Medicare began ﬁnancing renal care failure treatment in the 1970s
for people over and under 65; high rates of treatment resulted across all ages. In
contrast, the English NHS has severely rationed treatment for renal failure; not
surprisingly, recent UK rates of treatment per capita for the over 55s were 30% of
the US rate. Specialists providing renal services in England, however, never were
forced to turn anyone away: other doctors decided which patients suffering
from renal failure ought to be referred to the specialists providing treatments for
renal failure. In doing so they informally employed ideas of lifetime rationing and
cost-effectiveness, well before NICE formally adopted similar approaches starting
in 1999 (Aaron and Schwartz, 1984).
The second example is prescription drugs. In England, drugs prescribed by GPs
are subject to a copayment (of nearly £8), but many people are exempt from this
charge including anyone over 60 (5 years younger than the Medicare age
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threshold) provided the drugs have been approved by NICE (NHS Choices,
2014). Despite public perceptions to the contrary, the English NHS must provide
all medicines NICE has approved free-of-charge for those suffering from cancer,
heart disease or other chronic conditions, or for people over 60. If a patient over
60 wants to take a drug not approved by NICE, he or she must pay an effective
co-pay to cover the difference between the value NICE computed and the drug’s
actual cost (Faden and Chalkidou, 2011). In 2011, NICE extended its approval
for some drugs for the treatment Alzheimer’s disease, which had been restricted to
those with moderate disease to mild disease (NICE, 2011). In the United States,
Medicare Part D began providing drug coverage for Medicare beneﬁciaries in
2006 (before 2006, Medicare enrolees had to pay for all prescriptions outside the
hospital setting out-of-pocket or through supplemental drug insurance). Any drug
prescribed by the patient’s doctor is de facto covered, as there is no American
NICE equivalent for pharmaceuticals. Unlike in the NHS, however,Medicare Part
D plans include a deductible and a 25% co-payment up to an initial coverage
limit, after which the Medicare enrolee pays the full cost of prescriptions until the
full out-of-pocket threshold is reached. The ACAwill eliminate that coverage gap,
the so-called ‘donut hole’, by 2020. Until then, however, the United States clearly
will continue rationing prescription drugs for its Medicare beneﬁciaries on the
basis of ability to pay, which disproportionally impacts those suffering from
chronic conditions. People 65 and older with two or more chronic conditions are
about as likely to ﬁll initial prescriptions in both the United States and England but
older Americans vs their English counterparts are more likely to let prescriptions
lapse because of cost concerns (Morgan and Kennedy, 2010).
The third example is obesity, which is one of the leading risk factors associated
with multiple chronic diseases, including heart disease, diabetes and many cancers
on both sides of the Atlantic. Medicare covers bariatric surgery for Medicare
beneﬁciaries suffering from type 2 diabetes, hypertension, coronary artery disease
or arthritis who are also morbidly obese, deﬁned as having a body mass index
(BMI) of at least 35. That is an example of a Medicare National Coverage
Determination (NCD), an assessment by Medicare’s medical team that deﬁnes
who is eligible for any new treatment: a positive NCD does not automatically
follow an approval by the US Food and Drug Administration (FDA). Even though
the NCD contains a public comment period, in which, by US law, agencies are
required to solicit and consider the views and recommendations of the public, the
NCD methodology is notably opaque, in contrast to NICE’s commitment to
transparency at each step of its evaluative and decision processes. Subsequent to a
positive NCD decision, Medicare assigns a price to each treatment, technology,
procedure or drug, which it updates every year.Medicare no longer mandates that
the bariatric surgeries it covers occur in certain high-volume hospital settings only.
(Centers for Medicare and Medicaid Services, 2013). In England, NICE guidance
says that anyone with a BMI of 40 or more can be considered for bariatric surgery,
as can those who would also qualify under Medicare’s criteria: i.e., those with a
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BMI of at least 35 with an obesity-related chronic condition. Both Medicare
and the NHS have explicitly disqualiﬁed those with a BMI less than 35 from
coverage, even though in 2011, the FDA approved bariatric surgery for people
with a BMI between 30 and 35 based on recent scientiﬁc ﬁndings that people in
that category experienced improved health and fewer diabetes-related complica-
tions post surgery (FDA, 2011).
Although the explicit rationing policies are the same for bariatric surgery in
Medicare and the NHS, actual access varies. In Medicare, if someone meets the
eligibility criteria for bariatric surgery, he or she will be able to get the surgery
performed at an approved hospital (albeit often with a 2–3 months wait). As with
all inpatient and outpatient services, however, bariatric surgery for Medicare
enrolees carries a variety of co-payments, up to an out-of-pocket maximum
threshold across all inpatient services. Even within Medicare, this is another
example of rationing by ability to pay because of the cumulative impact of the
requirement for co-payments on people with multiple chronic conditions. In the
NHS in England, lack of resources has resulted in many purchasers and GPs
denying patients what NICE deems to be cost-effective bariatric surgery on the
grounds that it is too costly, with many restricting bariatric surgery only to those
with a BMI of 50 or above, and even then often requiring waits of 6 months or
more (Royal College of Surgeons, 2010). Owen-Smith et al. (2013) highlighted
the scale of rationing: ‘less than 0.6% of those who are potentially eligible for
bariatric surgery receive treatment on the NHS’. Sir Bruce Keogh is reported as
saying that there was ‘probably quite a strong case for us changing the threshold at
which we offer bariatric surgery’ to treat morbid obesity (UKHouse of Commons,
Committee of Public Accounts, 2013, ev 25). Owen-Smith et al. report that the
NHS atlas (NHS, 2010) identiﬁed 93-fold variation in rates of bariatric surgery
in England across 150 purchasers in England (over the period 2007–2008 to
2008–2009 after standardising for age and sex); and which, as Owen-Smith et al.
point out, cannot be explained by differences in the prevalence of simple obesity.
They argue that purchasers will struggle to achieve fairness and equity of provi-
sion in the current period of austerity.
Discussion
This article has argued that the differing powers of the executive arms of govern-
ment have shaped the political settlements of the landmark legislative reforms of
health care in the United States and England, which have in turn created different
institutional arrangements with their own ‘accidental logics’. The institutional
arrangements in England are that the government decides the total budget for the
NHS, how that is distributed and thus sets the context for the rationing of
care; and, in the United States, the government’s role within health care is in the
main limited to being an additional third party payer. The outcomes of these
institutional arrangements are stark differences in terms of total costs of health
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care, coverage, the geographical distribution of resources, and the ‘accidental
logics’ of what types of rationing of health care are and are not acceptable: in
England it is accepted that within the NHS some beneﬁcial health care will not be
provided because it is too costly and it is unacceptable that access would depend
on ability to pay; and in the United States the converse applies. As the reason for
the differences in total costs is likely to be from differences in the uptake of new
developments in technology for the elderly, we have examined how different
institutional arrangements impact on the care of the elderly, in the United States
and England for acute and EOL care, where technology matters, and chronic care,
where technology is much less important.
The two comparative studies of acute care in Britain and the United States in the
1980s (Aaron and Schwartz, 1984) and 2000s (Aaron et al., 2005) found stronger
indications of lifetime rationing in the English NHS in the 1980s, a decade of
severe resource constraints, than in the 2000s, a decade of increasing resources.
But even after that substantial increase in NHS funding, the British rates for renal
failure, coronary artery surgery, knee replacements, and use of CT scanners and
MRI equipment were still below those for the United States. Recent studies suggest
that, in the English NHS, the elderly are being denied beneﬁcial surgery for hip
and knee replacements, and cataracts. For EOL care, despite common objectives
in both countries, the different institutional arrangements tend to mean more
aggressive interventions in the United States and awareness of their opportunity
costs in England. For chronic care: rates of treatment are higher in the United
States than the United Kingdom for renal failure, which is funded by Medicare;
the NHS has more generous coverage in providing prescription drugs without
co-payment, although this ‘donut hole’ in the United States will eventually be ﬁlled
by the ACA; and for bariatric surgery, rationing in England is by local purchasers
and GPs as gatekeepers, which may or may not follow NICE guidance, and in
the United States by individuals’ responses to arrangements for cost sharing.More
generally, in the United States it is toxic even to broach a topic that could be
interpreted as lifetime rationing of Medicare enrollees (as illustrated by the furor
about ‘death panels’) with an unintended consequence of rationing care for many
poor Americans.
We began by pointing out how the current reforms to health care demonstrate the
comparative power of the executive in England to impose top-down changes on the
NHS and the comparative vulnerability of the executive in the United States to
current vested interests from insurers and providers. In England the latest attempt to
make provider competition generate incentives for improved performance has been
implemented in an era of severe cost constraints with questions over how rationing
will apply to the joint cost pressures froman ageing population and developments in
technology. The legislative and constitutional proscription of lifetime rationing
within the NHS removes what Daniels and Dworkin argued provides a sound basis
of responding to those pressures. In the absence of lifetime rationing, the alternative
formal bases of rationing are: using a modiﬁed form of cost-effectiveness that
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ignores differences in life expectancy, which raises formidable problems of inter-
personal comparisons; or a lottery. In practice, a different kind of lottery is likely
to develop which lacks the transparency of explicit deliberative approaches: by
purchasers, with questions over ‘postcode rationing’; and implicitly by doctors,
making the complex clinical judgements over the beneﬁts of treatment for the old as
compared with the young, similar to that of the 1980s, as described by Aaron
and Schwartz (1984). For the United States, the problem and central question are
different. The political settlement that delivered the ACA is one of expansion in
coverage (though perhaps, after the Supreme Court’s ruling, less by means of
Medicaid than was initially envisaged), with little real prospect of controlling
escalation in costs. So, how will the system pay for the elderly and young alike, and
in particular for new treatments for an ageing population? And will the elderly still
have priority over those who are younger and poor?
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